Jin Medical International (NASDAQ:ZJYL) versus MacroGenics (NASDAQ:MGNX) Head to Head Contrast

Jin Medical International (NASDAQ:ZJYL) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jin Medical International and MacroGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jin Medical International	1	0	0	0	1.00
MacroGenics	1	3	3	0	2.29

MacroGenics has a consensus price target of $5.50, indicating a potential upside of 32.21%. Given MacroGenics’ stronger consensus rating and higher probable upside, analysts plainly believe MacroGenics is more favorable than Jin Medical International.

Risk and Volatility

Jin Medical International has a beta of 7.52, meaning that its stock price is 652% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Insider and Institutional Ownership

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Jin Medical International and MacroGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jin Medical International	N/A	N/A	N/A
MacroGenics	-44.79%	-147.80%	-28.40%

Earnings and Valuation

This table compares Jin Medical International and MacroGenics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jin Medical International	$20.69 million	0.85	$1.19 million	N/A	N/A
MacroGenics	$149.50 million	1.77	-$74.62 million	($1.10)	-3.78

Jin Medical International has higher earnings, but lower revenue than MacroGenics.

Summary

MacroGenics beats Jin Medical International on 7 of the 12 factors compared between the two stocks.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.

About MacroGenics

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.